Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus

@article{Britton1998EffectsOG,
  title={Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus},
  author={M. Britton and A. E. Denver and V. Mohamed-ali and J. Yudkin},
  journal={Clinical Drug Investigation},
  year={1998},
  volume={16},
  pages={303-317}
}
AbstractObjective: This study aimed to compare the effects of glimepiride and glibenclamide on glycaemic control and a range of risk factors for ischaemic heart disease (IHD), including concentrations of insulin-like molecules. Patients: A double-blind, placebo-controlled, randomised, crossover comparison of 4 weeks of treatment with glibenclamide 2.5 to 20 mg/day and glimepiride 1 to 8 mg/day was undertaken in 29 type 2 (non-insulin-dependent) diabetic patients. The average (mean ±SD… Expand

References

SHOWING 1-10 OF 51 REFERENCES
How Does Glibenclamide Lower Plasma Glucose Concentration in Patients with Type 2 Diabetes?
...
1
2
3
4
5
...